Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
NCT ID: NCT07066813
Last Updated: 2025-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2025-06-01
2026-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes?
* How do imaging features of cystic lesions correlate with their pathological characteristics?
* What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis?
* Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multi-omics Study of Early-stage Lung Cancer with Distinct Phenotypes
NCT06699979
Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery
NCT06483698
Prognostic Significance of the Uncertain Resection in NSCLC
NCT06511661
Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC
NCT07186855
Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery
NCT05648370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1
radiologic T stage based on the maximum tumor diameter including cystic components
No interventions assigned to this group
group 2
radiologic T stage based on the diameter of the solid/invasive portion only
No interventions assigned to this group
group 3
pathologic T stage derived from the resected specimen
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who have undergone surgical lung resection;
3. Patients with complete preoperative chest CT imaging data;
4. Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.
Exclusion Criteria
2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
3. Patients with concurrent other malignancies;
4. Patients with missing or poor-quality preoperative chest CT imaging data.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chen Chen
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LYEC2025-K0017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.